Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin

被引:263
作者
Wu, Chengbin
Ying, Hua
Grinnell, Christine
Bryant, Shaughn
Miller, Renee
Clabbers, Anca
Bose, Sahana
McCarthy, Donna
Zhu, Rong-Rong
Santora, Ling
Davis-Taber, Rachel
Kunes, Yune
Fung, Emma
Schwartz, Annette
Sakorafas, Paul
Gu, Jijie
Tarcsa, Edit
Murtaza, Anwar
Ghayur, Tariq
机构
[1] Abbott Res Ctr, Dept Biolog, Worcester, MA 01605 USA
[2] Abbott Res Ctr, Discovery Ssafety Metab & Pharmacokinet, Worcester, MA 01605 USA
[3] Abbott Res Ctr, Dept Pharmacol, Worcester, MA 01605 USA
[4] Abbott Res Ctr, Dept Proc Sci, Worcester, MA 01605 USA
关键词
D O I
10.1038/nbt1345
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
For complex diseases in which multiple mediators contribute to overall disease pathogenesis by distinct or redundant mechanisms, simultaneous blockade of multiple targets may yield better therapeutic efficacy than inhibition of a single target. However, developing two separate monoclonal antibodies for clinical use as combination therapy is impractical, owing to regulatory hurdles and cost. Multi-specific, antibody-based molecules have been investigated; however, their therapeutic use has been hampered by poor pharmacokinetics, stability and manufacturing feasibility. Here, we describe a generally applicable model of a dual-specific, tetravalent immunoglobulin G (IgG)-like molecule-termed dual-variable-domain immunoglobulin (DVD-Ig)-that can be engineered from any two monoclonal antibodies while preserving activities of the parental antibodies. This molecule can be efficiently produced from mammalian cells and exhibits good physicochemical and pharmacokinetic properties. Preclinical studies of a DVD-Ig protein in an animal disease model demonstrate its potential for therapeutic application in human diseases.
引用
收藏
页码:1290 / 1297
页数:8
相关论文
共 40 条
[1]  
Abbott GmbH and Co KG, 2005, [No title captured], Patent No. [US6914128B1, 6914128]
[2]   Cytokines and cellular interactions in inflammatory synovitis [J].
Arend, WP .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) :1081-1082
[3]  
Arndt Michaela, 2003, Methods Mol Biol, V207, P305
[4]  
BONARDI MA, 1993, CANCER RES, V53, P3015
[5]  
CHEONG HS, 1990, BIOCHEM BIOPH RES CO, V173, P795
[6]   ROLE OF THE BP35 CELL-SURFACE POLYPEPTIDE IN HUMAN B-CELL ACTIVATION [J].
CLARK, EA ;
SHU, G ;
LEDBETTER, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (06) :1766-1770
[7]   PRODUCTION OF NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12) BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS [J].
DANDREA, A ;
RENGARAJU, M ;
VALIANTE, NM ;
CHEHIMI, J ;
KUBIN, M ;
ASTE, M ;
CHAN, SH ;
KOBAYASHI, M ;
YOUNG, D ;
NICKBARG, E ;
CHIZZONITE, R ;
WOLF, SF ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1387-1398
[8]  
DINARELLO CA, 2000, CURRENT PROTOCOLS IM
[9]  
GHAYUR T, 2005, Patent No. 37971
[10]   Engineered antibody fragments and the rise of single domains [J].
Holliger, P ;
Hudson, PJ .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1126-1136